-
Something wrong with this record ?
Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack
M. Wawruch, D. Zatko, G. Wimmer, J. Luha, S. Wimmerova, P. Matalova, P. Kukumberg, J. Murin, T. Tesar, B. Havelkova, R. Shah,
Language English Country New Zealand
Document type Journal Article
NLK
ProQuest Central
from 2008-06-01 to 1 year ago
Health & Medicine (ProQuest)
from 2008-06-01 to 1 year ago
- MeSH
- Medication Adherence * MeSH
- Diabetes Mellitus epidemiology MeSH
- Hypercholesterolemia drug therapy MeSH
- Cohort Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Polypharmacy MeSH
- Proportional Hazards Models MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use MeSH
- Ischemic Attack, Transient drug therapy MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND AND OBJECTIVE: Non-persistence with secondary preventive measures, including medications such as statins, adversely affects the prospects of successful outcomes. This study was aimed at evaluating non-persistence with statin therapy in cohorts of young and elderly patients after a transient ischaemic attack (TIA) and identifying patient-associated characteristics that influence the risk for non-persistence. METHODS: The study cohorts included 797 adult patients who were initiated on statin therapy following a TIA diagnosis between 1 January 2010 and 31 December 2010. Patients were followed up for 3 years and those with a treatment gap of at least a 6-month period were considered 'non-persistent'. In order to identify any age-related differences, all analyses were conducted in the entire study cohort (n = 797) as well as separately in the 'younger' (aged <65 years, n = 267) and the 'older' (aged ≥65 years, n = 530) patients. RESULTS: Non-persistence was significantly more common in younger patients compared to older patients (67.8% vs. 49.1%; p < 0.001). Factors that decreased the probability of non-persistence in younger and older patients included diabetes mellitus (hazard ratio [HR] = 0.72 and HR = 0.64, respectively) and hypercholesterolaemia (HR = 0.43 and HR = 0.62, respectively). Female gender (HR = 1.42) was associated with a higher and increasing number of medications taken (HR = 0.93), with lower probability for non-persistence in younger patients but not in the older patients. CONCLUSIONS: Our results indicate that certain patients with TIA require special counselling to improve persistence with statin therapy. These include younger patients, especially females and those not on polypharmacy, and both younger and older patients without diabetes mellitus or hypercholesterolaemia.
General Health Insurance Company Panónska cesta 2 851 04 Bratislava Slovakia
Independent Pharmaceutical Consultant 8 Birchdale Gerrards Cross Buckinghamshire SL9 7JA UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024750
- 003
- CZ-PrNML
- 005
- 20180712100708.0
- 007
- ta
- 008
- 180709s2017 nz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s40261-017-0559-3 $2 doi
- 035 __
- $a (PubMed)28791591
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a nz
- 100 1_
- $a Wawruch, Martin $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia. martin.wawruch@gmail.com.
- 245 10
- $a Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack / $c M. Wawruch, D. Zatko, G. Wimmer, J. Luha, S. Wimmerova, P. Matalova, P. Kukumberg, J. Murin, T. Tesar, B. Havelkova, R. Shah,
- 520 9_
- $a BACKGROUND AND OBJECTIVE: Non-persistence with secondary preventive measures, including medications such as statins, adversely affects the prospects of successful outcomes. This study was aimed at evaluating non-persistence with statin therapy in cohorts of young and elderly patients after a transient ischaemic attack (TIA) and identifying patient-associated characteristics that influence the risk for non-persistence. METHODS: The study cohorts included 797 adult patients who were initiated on statin therapy following a TIA diagnosis between 1 January 2010 and 31 December 2010. Patients were followed up for 3 years and those with a treatment gap of at least a 6-month period were considered 'non-persistent'. In order to identify any age-related differences, all analyses were conducted in the entire study cohort (n = 797) as well as separately in the 'younger' (aged <65 years, n = 267) and the 'older' (aged ≥65 years, n = 530) patients. RESULTS: Non-persistence was significantly more common in younger patients compared to older patients (67.8% vs. 49.1%; p < 0.001). Factors that decreased the probability of non-persistence in younger and older patients included diabetes mellitus (hazard ratio [HR] = 0.72 and HR = 0.64, respectively) and hypercholesterolaemia (HR = 0.43 and HR = 0.62, respectively). Female gender (HR = 1.42) was associated with a higher and increasing number of medications taken (HR = 0.93), with lower probability for non-persistence in younger patients but not in the older patients. CONCLUSIONS: Our results indicate that certain patients with TIA require special counselling to improve persistence with statin therapy. These include younger patients, especially females and those not on polypharmacy, and both younger and older patients without diabetes mellitus or hypercholesterolaemia.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a diabetes mellitus $x epidemiologie $7 D003920
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a hypercholesterolemie $x farmakoterapie $7 D006937
- 650 _2
- $a tranzitorní ischemická ataka $x farmakoterapie $7 D002546
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a adherence k farmakoterapii $7 D055118
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a polypharmacy $7 D019338
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zatko, Dusan $u General Health Insurance Company, Panónska cesta 2, 851 04, Bratislava, Slovakia.
- 700 1_
- $a Wimmer, Gejza $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia.
- 700 1_
- $a Luha, Jan $u Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia.
- 700 1_
- $a Wimmerova, Sona $u Department of Biophysics, Informatics and Biostatistics, Faculty of Public Health, Slovak Medical University, Limbová 12, 833 03, Bratislava, Slovakia.
- 700 1_
- $a Matalova, Petra $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
- 700 1_
- $a Kukumberg, Peter $u 2nd Department of Neurology, Faculty of Medicine, Comenius University, Limbová 5, 833 05, Bratislava, Slovakia.
- 700 1_
- $a Murin, Jan $u 1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Mickiewiczova 13, 813 69, Bratislava, Slovakia.
- 700 1_
- $a Tesar, Tomas $u Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Kalinciakova 8, 832 32, Bratislava, Slovakia.
- 700 1_
- $a Havelkova, Beata $u General Health Insurance Company, Panónska cesta 2, 851 04, Bratislava, Slovakia.
- 700 1_
- $a Shah, Rashmi $u Independent Pharmaceutical Consultant, 8 Birchdale, Gerrards Cross, Buckinghamshire, SL9 7JA, UK.
- 773 0_
- $w MED00001123 $t Clinical drug investigation $x 1179-1918 $g Roč. 37, č. 11 (2017), s. 1047-1054
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28791591 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712101001 $b ABA008
- 999 __
- $a ok $b bmc $g 1316881 $s 1021671
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 37 $c 11 $d 1047-1054 $i 1179-1918 $m Clinical drug investigation $n Clin. drug invest. $x MED00001123
- LZP __
- $a Pubmed-20180709